NEW YORK (GenomeWeb) – The UK's National Institute for Health and Care Excellence (NICE) has included three molecular diagnostics — Myriad Genetics' EndoPredict, NanoString's Prosigna, and Genomic Health's Oncotype DX — in recommendations for tests guiding chemotherapy decisions for early-stage breast cancer patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.